Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

October 21, 2025 04:00 ET | Source: AKAMPION

selectION Demonstrates Safety and Disease-Modifying Mechanism of Action of its Investigational Drug, si-544, in Phase 1b Proof-of-Concept Trial in Psoriasis, a T Cell-Mediated Autoimmune Disease

Disease modifying mechanism of action: short treatment course results in significant and durable clinical response in psoriasis patients si-544 is the first highly potent and selective Kv1.3 blocker...
October 20, 2025 04:00 ET | Source: AKAMPION

ImmunOs Therapeutics Reports Promising Clinical Activity of IOS-1002 in Advanced Solid Tumors

Partial remissions and complete metabolic responses in PD-1/PD-L1-resistant cancersFirst-in-class multi-checkpoint inhibitor with robust efficacy and safetyCombination arm with pembrolizumab...
September 25, 2025 08:30 ET | Source: Tevogen Bio Inc

Tevogen Marks Major Milestone in Its AI Initiative to Enhance Efficacy of T Cell–Based Therapies with 100x PredicTcell™ Beta Data Expansion

Beta version of PredicTcell™ expands training dataset to ~1.4 million and total dataset to over 6.7 billion records.Potential future T cell therapies could reliably bind to their target nearly every...
December 09, 2024 04:00 ET | Source: AKAMPION

tiakis Biotech AG Reports Clinical Phase Ib/II Trial Results of Tiprelestat for the Treatment of Hospitalized COVID-19 Patients

- Tiprelestat was safe and well tolerated, with initial signs of clinical efficacy Kiel, Germany, December 9, 2024 – tiakis Biotech AG, a clinical-stage biopharmaceutical company developing...
October 31, 2024 10:00 ET | Source: Vaccinex, Inc.

Vaccinex Reports New Findings for SIGNAL-AD Phase 1b/2 Trial of Pepinemab at Clinical Trials on Alzheimer’s Disease (CTAD) Conference in Madrid, Spain

ROCHESTER, N.Y., Oct. 31, 2024 (GLOBE NEWSWIRE) -- Vaccinex (Nasdaq: VCNX) today provided an update on new clinical findings from its SIGNAL-AD Phase 1b/2 trial of pepinemab antibody in Alzheimer’s...
May 27, 2024 10:31 ET | Source: The Rosen Law Firm PA

GLOBALLY RECOGNIZED ROSEN LAW FIRM Encourages Altimmune, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action – ALT

NEW YORK, May 27, 2024 (GLOBE NEWSWIRE) -- WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of securities of Altimmune, Inc. (NASDAQ: ALT) between December 1, 2023 and...
March 21, 2024 07:00 ET | Source: OKYO Pharma LTD

OKYO Pharma to Host Key Opinion Leader Event to Discuss New and Comprehensive Data from Phase 2 Dry Eye Disease Trial

-Phase 2 OK-101 efficacy data to be released March 22nd, 2024- -KOL Event to be held on April 9th, 2024 at 12 PM ET- LONDON and NEW YORK, March 21, 2024 (GLOBE NEWSWIRE) -- OKYO Pharma Limited...
March 20, 2024 07:00 ET | Source: OKYO Pharma LTD

OKYO Pharma to Release New and Comprehensive Data from Phase 2 Dry Eye Disease Trial and Host Key Opinion Leader Event

LONDON and NEW YORK, March 20, 2024 (GLOBE NEWSWIRE) -- OKYO Pharma Limited (NASDAQ: OKYO), a clinical-stage biopharmaceutical company developing innovative ocular therapies for the treatment of...
December 18, 2023 09:00 ET | Source: Cyclacel

Cyclacel Pharmaceuticals Reports Fadraciclib Phase 1 Data Suggesting Efficacy Against Tumors With CDKN2A, CDKN2B and MTAP Deletions

- Patient Pharmacodynamic Data Show Decrease in CDKN2A, CDKN2B, and PRMT5 Protein Levels - - A Squamous Non-Small Cell Lung Cancer Patient with CDKN2B Deletion Achieved Marked Tumor Shrinkage...
December 12, 2023 07:31 ET | Source: Emergen Research

Clinical Biomarkers Market Size to Reach USD 63.04 Billion in 2032 | Emergen Research

Vancouver, Dec. 12, 2023 (GLOBE NEWSWIRE) -- The global clinical biomarkers market is expected to reach a market size of USD 63.04 billion at a steady CAGR of 10.2% in 2032, according to latest...